CPRX catalystpharma.com Company Future Sales Volume
Catalyst Pharmaceuticals relies on digital supply logistics and a monopoly in the treatment of Lambert-Eaton myasthenic syndrome. The firm's future sales trend demonstrates long-term capital potential, with 0.76 serving as the current value of the indicator. Business resilience is based on Firdaps patents and regulatory approvals, which determine the company's market success in neuropharmaceuticals.
Financial and market metric breakdowns for Catalyst Pharma (CPRX)
- stock value and consensus price forecast:
- market capitalization data:
- issuer book value statistics:
- debt and solvency information:
Total Debt to Capital Catalyst Pharmaceuticals|CPRX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Catalyst Pharmaceuticals Inc|CPRX - Company Aggregate Debts|Debt to Book Capitalization Ratio Catalyst Pharma|CPRX - Company Long-Term Loans and Borrowings|Company Short-Term Debt Catalyst Pharmaceuticals|Quick Ratio catalystpharma.com
- financial results and valuation multiples details:
CPRX - Net Profit|Projected Future Earnings Catalyst Pharmaceuticals|CPRX - Price to Earnings Ratio|Forward P/E Multiple Catalyst Pharmaceuticals, Inc.|CPRX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Catalyst Pharma|CPRX - Operating profit EBITDA|Net earnings per share for the last 12 months Catalyst Pharmaceuticals|CPRX - Earnings per share for the last four quarters|Quarterly EPS earnings growth catalystpharma.com|CPRX - Expected net earnings per share growth this year|Earnings growth forecast for next year Catalyst Pharmaceuticals
- sales volume and revenue information:
Comprehensive company analysis:CPRX Catalyst Pharmaceuticals
For Catalyst Pharmaceuticals (CPRX), which has outsourced production and testing to third-party contractors (CRO/CMO), this indicator allows for an assessment of this model's efficiency through the lens of future cash flows. The mathematical revenue projection, reflected in the firm's estimated sales volume, separates market noise from systemic trends, helping investors identify the point of fundamental undervaluation for long-term investment.
Direct competitors
Company Projected Revenue Biogen Inc. (BIIB)|Company Future Sales neurocrine.com|Regencell Bioscience Holdings Limited - Company Future Sales Volume|Company Projected Revenue Volume AXSM (Axsome)|ACAD: Company Future Sales Volume|Company Future Revenue XENE (Xenon Corp)|Viking Therapeutics (VKTX) - Company Projected Revenue|Company Expected Revenue SUPN (supernus.com)|DNLI (Denali Therapeutics Inc.) - Projected Sales Volume|HRMY: Company Future Revenue|Projected Sales Volume BHVN|Projected Sales Volume Amylyx Corp (AMLX)|Company Projected Revenue Trevi Therapeutics TRVI|Company Future Revenue PRAX|AVXL - Company Projected Revenue|CeriBell Inc (CBLL) - Company Future Sales Volume|PRTA: Projected Sales Volume|Alector (ALEC) - Projected Sales Volume|ANNX (Annexon, Inc.) - Projected Sales Volume|Company Future Sales Volume Omeros Corp. (OMER)|Projected Sales Volume NGNE|ACIU - Company Expected Sales Volume|Voyager Pharma - Company Future Sales Volume|Projected Sales Volume Neumora Corp NMRA|SCLX: Company Future Sales Volume|tevogen.com - Company Projected Revenue Volume|ACOG: Projected Sales Volume|CGTX - Company Future Sales|IKT (Inhibikase) - Projected Sales Volume|Company Future Sales Volume Cassava Pharma (SAVA)|Projected Sales Volume ASRT|Projected Sales Volume coyatherapeutics.com (COYA)|Company Projected Revenue Vistagen VTGN|Ovid Therapeutics Inc - Company Projected Revenue|ABOS - Company Projected Revenue|Company Future Sales CervoMed Corporation CRVO|ATHE: Projected Sales Volume|Company Future Sales Volume Clene|Company Projected Revenue PepGen Inc|jupiterneurosciences.com - Company Expected Revenue|Company Projected Revenue Relmada (RLMD)|ANVS (Annovis Bio Corporation) - Company Future Revenue|Grace Therapeutics - Company Future Sales Volume|AIFF: Company Revenue Forecast|KLTO - Company Projected Revenue|NRSN (NeuroSense Therapeutics) - Company Revenue Forecast|RVPH: Projected Sales Volume|Company Expected Sales Volume MetaVia (MTVA)|Company Future Sales Volume NRXS|Projected Sales Volume Helius Medical Technologies Inc.|Company Projected Revenue Passage Bio, Inc. (PASG)|NEUP (bionomics.com.au) - Company Future Revenue|Company Projected Revenue Minerva Neurosciences Corp NERV|Athira Pharma Corp (ATHA) - Company Expected Sales Volume|Addex Therapeutics - Projected Sales Volume|Alzamend Neuro, Inc. (ALZN) - Company Future Sales Volume|CYCN: Projected Sales Volume|Protagenic Therapeutics, Inc. (PTIX) - Projected Sales Volume|Company Future Sales Volume KTTA|CRGT (Cortigent Medical) - Company Projected Revenue Volume|Projected Sales Volume ATXI|Projected Sales Volume brainstorm-cell.com (BCLI)|Company Projected Revenue Cara Therapeutics CARA|Chromocell Therapeutics Corp - Company Projected Revenue|ELYM: Company Future Sales Volume|Company Expected Sales Volume Intra-Cellular Therapies|Longboard Pharmaceuticals (LBPH) - Company Projected Revenue|MRNS - Company Future Sales|Company Future Sales Volume NKGN|NRBO (NeuroBo Pharmaceuticals Inc) - Company Projected Revenue Volume|Company Future Sales Volume SAGE (Sage Therapeutics, Inc)|SNPX (Synaptogenix, Inc) - Company Future Revenue|Company Projected Revenue Trevena, Inc. TRVN|VIGL (Vigil Neuroscience Inc.) - Company Expected Revenue|Anew Medical, Inc. - Projected Sales Volume|Company Future Revenue CERE (Cerevel Therapeutics Inc)
